US 11,701,367 B2
Ganaxolone for use in treating tuberous sclerosis complex
Alex Aimetti, Radnor, PA (US); Joseph Hulihan, Radnor, PA (US); and Scott Braunstein, Radnor, PA (US)
Assigned to Marinus Pharmaceuticals, Inc., Radnor, PA (US)
Filed by Marinus Pharmaceuticals, Inc., Radnor, PA (US)
Filed on Mar. 1, 2022, as Appl. No. 17/683,624.
Application 17/683,624 is a continuation of application No. PCT/US2020/063648, filed on Dec. 7, 2020.
Claims priority of provisional application 62/944,549, filed on Dec. 6, 2019.
Prior Publication US 2022/0211723 A1, Jul. 7, 2022
Int. Cl. A61K 31/57 (2006.01); A61P 25/08 (2006.01)
CPC A61K 31/57 (2013.01) [A61P 25/08 (2018.01)] 25 Claims
OG exemplary drawing
 
1. A method for treating tuberous sclerosis-related epilepsy comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone, wherein the therapeutic effectively amount is administered orally three times per day.